Carcinoma Cancer Articles & Analysis
26 news found
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which ...
xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients often have malignant fluid drained to provide symptomatic relief. ...
ByxCures
AFM24 activates the innate immune system to kill cancer cells by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors. ...
“Senti Bio’s use of Logic Gated gene circuits in its off-the-shelf CAR-NK designs has the potential to selectively target tumors while sparing healthy cells and, I believe, expand the cell therapy opportunity to additional tumor types including acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer and others. I am also drawn to the broad ...
SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while sparing healthy cells SENTI-301 poster presentation highlights optimization of Multi-Arming and Regulator Dial Gene Circuits to improve the cytotoxicity of allogeneic CAR-NK cells and immune ...
Session date/time: May 16, 5:30 - 6:30 p.m. EDT Session title: Cancer - Targeted Gene and Cell Therapy I Abstract: #352 Poster: #M-233 Activation regulated gene circuit for controlling payload expression in cell therapies, Hung et al. ...
The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC). Patients will receive a single Eye90 microspheres radioembolization treatment with follow-up visits for one year to assess safety, effectiveness, and ...
Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...
Senti Bio’s gene circuit technology is being applied in the design of multiple product candidates including SENTI-202 for the potential treatment of acute myeloid leukemia (AML), SENTI-301 for the potential treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the potential treatment of colorectal cancer (CRC). ...
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022. ...
” Tweet this “To our knowledge, this is the first randomized clinical trial to demonstrate that a live bacterial product can modulate the gastrointestinal microbiome and enhance immunotherapy response in cancer patients. These results can help improve treatment options for patients with kidney cancer and is an important foundational step to bring ...
Please see FOTIVDA Full Prescribing Information which is available at www.FOTIVDA.com. About Advanced Renal Cell Carcinoma According to the American Cancer Society’s 2021 statistics, renal cell carcinoma (RCC) is the most common type of kidney cancer, which is among the ten most common cancers in both men ...
Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...
Please see FOTIVDA Full Prescribing Information which is available at www.FOTIVDA.com. About Advanced Renal Cell Carcinoma According to the American Cancer Society’s 2021 statistics, renal cell carcinoma (RCC) is the most common type of kidney cancer, which is among the ten most common cancers in both men ...
The prospective, single-center, open-label study will evaluate the safety and effectiveness of Eye90 microspheres™ in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC). Patients will receive a single Eye90 microspheres radioembolization treatment with follow-up visits for one year to assess safety, ...
One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ...
Tom is working with Michelson to develop AI software that will process images of basal cell carcinoma, the most common form of skin cancer affecting millions worldwide, scanned by dermatologists using the innovative VivoSight™ OCT scanner already manufactured by Michelson Diagnostics. The AI will rapidly detect markers for basal cell ...
SFA is focused on proprietary drugs to treat chronic inflammation, which been implicated in a wide range of diseases, including Hepatocellular Carcinoma (liver cancer), Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn’s Disease, and Chronic Liver Disease. SFA currently has six drugs under development, and is ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the European label for KEYTRUDA, Merck’s anti-PD-1 therapy, be updated to include data from KEYNOTE-361, a Phase 3, open-label trial that evaluated KEYTRUDA ...
The surgical and radiation oncology team at Providence Mission Hospital (Mission Viejo, Ca) elected to use a novel tumor bed marker called VeraForm for a sarcomatoid carcinoma. Led by James Bredenkamp, M.D. and Quang Luu, M.D., this patient received a VeraForm marker when the lesion was surgically removed, representing a first of its kind for head and neck cancer ...